Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down prior to trading on Tuesday . The stock had previously closed at $10.19, but opened at $9.7899. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.75, with a volume of 6,315 shares trading hands.

Analyst Ratings Changes

Several brokerages have recently commented on SGIOY. Zacks Research cut shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company’s 50-day moving average is $10.94 and its 200-day moving average is $9.62. The firm has a market cap of $16.41 billion, a price-to-earnings ratio of 12.68, a price-to-earnings-growth ratio of 0.72 and a beta of 0.19. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.19 by $0.09. The business had revenue of $966.53 million during the quarter, compared to the consensus estimate of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. Equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.73 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.